Advertisement
Advertisement
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
71.45
USDSponsored
-1.36
-1.87%
Aug 25, 15:59 UTC -4
Closed
After-Market
71.47
+0.02
+0.02%
TARS Earnings Reports
Positive Surprise Ratio
TARS beat 16 of 24 last estimates.
67%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$182.99M
/-$1.20
Implied change from Q2 26 (Revenue/ EPS)
+5.22%
/+144.90%
Implied change from Q3 25 (Revenue/ EPS)
+54.16%
/+300.00%
Tarsus Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, TARS reported earnings of -0.49 USD per share (EPS) for Q2 26, missing the estimate of -0.19 USD, resulting in a -145.12% surprise. Revenue reached 173.91 million, compared to an expected 173.07 million, with a 0.49% difference. The market reacted with a +6.59% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -1.20 USD, with revenue projected to reach 182.99 million USD, implying an increase of 144.90% EPS, and increase of 5.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
CorMedix Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.24
Actual
$0.28
Surprise
+19.44%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Pelthos Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.10
Actual
-$6.62
Surprise
-112.99%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Kyntra Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.24
Actual
-$4.68
Surprise
-44.15%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
FAQ
What were Tarsus Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Tarsus Pharmaceuticals, Inc. Common Stock reported EPS of -$0.49, missing estimates by -145.12%, and revenue of $173.91M, 0.49% above expectations.
How did the market react to Tarsus Pharmaceuticals, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 6.59%, changed from $61.29 before the earnings release to $65.33 the day after.
When is Tarsus Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Tarsus Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 7
analysts, Tarsus Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$1.20 and revenue of $182.99M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement